{"id":"NCT03575052","sponsor":"ACADIA Pharmaceuticals Inc.","briefTitle":"A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease","officialTitle":"A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-21","primaryCompletion":"2022-05-06","completion":"2022-05-06","firstPosted":"2018-07-02","resultsPosted":"2024-12-31","lastUpdate":"2024-12-31"},"enrollment":784,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Neuropsychiatric Symptoms Related to Neurodegenerative Disease"],"interventions":[{"type":"DRUG","name":"Pimavanserin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Drug - Pimavanserin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease.","primaryOutcome":{"measure":"Treatment-emergent Adverse Events (TEAEs)","timeFrame":"Treatment Period: 8 weeks","effectByArm":[{"arm":"Placebo","deltaMin":115,"sd":null},{"arm":"Pimavanserin 34 mg","deltaMin":119,"sd":null}],"pValues":[]},"eligibility":{"minAge":"60 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":104,"countries":["United States","Bulgaria","Colombia","Czechia","Georgia","Mexico","Poland","Romania","Russia","Serbia","South Africa","Ukraine"]},"refs":{"pmids":["38427485"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":392},"commonTop":["Urinary tract infection"]}}